Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment

Accesswire January 31, 2019

Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment

Accesswire January 30, 2019

Theralase(R) Completes $1.4 M Private Placement Equity Financing

Accesswire January 9, 2019

Health Canada Grants ITA Approval to Commence Phase II Clinical Study

Accesswire December 10, 2018

Theralase’s Rutherrin(R) Photo Dynamic Therapy Induces Immune Response to Destroy Human Brain Cancer Cells

Accesswire November 30, 2018

Theralase Release 3Q2018 Financial Statements

Accesswire November 29, 2018

Theralase(R) Granted Canadian Anti-Cancer Patent

Accesswire November 15, 2018

Cancer Breakthrough Reported by Junior Biotech Company

Jeff Nielson November 15, 2018

Patient Five Cancer-Free After Single PDT Treatment

Accesswire November 8, 2018

Theralase(R) Anti-Cancer Technology Shows Promise for Esophageal Cancer Using Targeted Molecular Delivery System

Filing Services Canada October 9, 2018

Theralase Announces Completion of Non-Brokered Private Placement for Approximately $1.1 million

Filing Services Canada October 3, 2018

DealRoom: Advanced-Stage Biotech Company, Full Warrant

Stockhouse Editorial September 11, 2018

Health Canada Approves Commencement of Phase II Clinical Study

Filing Services Canada September 10, 2018

Theralases Lead Photodynamic Compound TLD-1433 Provides New Opportunities in Targeted Cancer Therapy

Filing Services Canada September 4, 2018

Theralase Announces Proposed Non-Brokered Private Placement of up to $10 Million

Filing Services Canada August 28, 2018

Theralase(R) Provides Update on Upcoming Initiatives for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Filing Services Canada August 27, 2018

Theralase Submits Phase II Bladder Cancer Clinical Study Application to Health Canada for Review and Approval

Filing Services Canada August 20, 2018

Breakthrough Cancer Therapy: More Progress in Clinical Study

Jeff Nielson August 16, 2018

Theralase Achieves Exploratory Efficacy Endpoint in Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study for Patients Five and Six

Filing Services Canada August 13, 2018

Theralase Release 2Q2018 Financial Statements

Filing Services Canada July 26, 2018